Hi-TIDe : LAbCore immunoglobulin discovery and engineering

Using proprietary platform capabilities, our mission is the de novo discovery and development (research-to-GMP) of immunoglobulins of high potential therapeutic interest that can be exploited for the clinical targeting of solid tumors and cancer-related disease processes.

• We are developing approaches for the efficient and effective isolation and optimization of fully human ‘warhead’ binder molecules using phage-display library technology. We constantly ask how best to design and construct such libraries and to subsequently select, screen and rank binders for downstream applications.
• In addition to fully in vitro discovery, we ask whether native immunoglobulins produced by tumor infiltrating B cells represent good starting points for the development of functional anti-tumor molecules.
• We have established a pipeline of novel CAR/BiTE-compatible molecules for downstream experimental evaluation and clinical translation.
• We are investigating the utility of  an engineered non-TCR immunoglobulin scaffold for the stringent and selective targeting of therapeutically disease-relevant pMHC complexes In parallel, we are using proprietary in vitro display technology to investigate the physical basis of TCR:pMHC recognition and to explore how we might best mitigate the potential for undesirable cross-reactivity of pMHC targeting agents.
• We support the advancement of existing global LCR therapeutic monoclonal antibody candidates by conducting directed optimization and humanization studies. Current examples are two potential ‘best-in-class’ humanized anti-TGFb mAbs with exquisite selectivity for discrete TGFb isoforms.
• We have established a significant program for the discovery and collaborative development of novel TEM1-targeting antibodies and their fragments. These are being evaluated in T cell redirection studies as BiTE^TMs and CARS, and also for their potential suitability in nuclear medicine and tumor imaging.